<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral tapentadol for cancer pain - Wiffen, PJ - 2015 | Cochrane Library</title> <meta content="Oral tapentadol for cancer pain - Wiffen, PJ - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011460.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral tapentadol for cancer pain - Wiffen, PJ - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011460.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011460.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Oral tapentadol for cancer pain" name="citation_title"/> <meta content="Philip J Wiffen" name="citation_author"/> <meta content="pwiffen@oxfordsrs.org.uk" name="citation_author_email"/> <meta content="Sheena Derry" name="citation_author"/> <meta content="Katrien Naessens" name="citation_author"/> <meta content="Oxford Radcliffe Trust/Health Education Thames Valley" name="citation_author_institution"/> <meta content="Rae Frances Bell" name="citation_author"/> <meta content="Haukeland University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD011460.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/09/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011460.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011460.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011460.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Neoplasms [*complications]; Pain [*drug therapy]; Phenols [*therapeutic use]; Randomized Controlled Trials as Topic; Receptors, Opioid, mu [*therapeutic use]; Tapentadol" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011460.pub2&amp;doi=10.1002/14651858.CD011460.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xsb6SJyC";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011460\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011460\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","th","ms","hr","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011460.pub2",title:"Oral tapentadol for cancer pain",firstPublishedDate:"Sep 25, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011460.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011460.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011460.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011460.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011460.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011460.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011460.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011460.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011460.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011460.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2580 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011460.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/full#CD011460-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/full#CD011460-sec-0057"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/full#CD011460-sec-0008"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/full#CD011460-sec-0013"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/full#CD011460-sec-0014"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/full#CD011460-sec-0037"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/full#CD011460-sec-0051"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/appendices#CD011460-sec-0067"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral tapentadol for cancer pain</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/information#CD011460-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Philip J Wiffen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/information#CD011460-cr-0005">Sheena Derry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/information#CD011460-cr-0006">Katrien Naessens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011460.pub2/information#CD011460-cr-0007">Rae Frances Bell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/information/en#CD011460-sec-0076">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 September 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011460.pub2">https://doi.org/10.1002/14651858.CD011460.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011460-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011460-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011460-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011460-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/th#CD011460-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011460-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011460-abs-0001" lang="en"> <section id="CD011460-sec-0001"> <h3 class="title" id="CD011460-sec-0001">Background</h3> <p>A large proportion of people with advanced cancer will experience moderate to severe pain. Tapentadol is a novel, centrally acting analgesic medicine acting at the μ‐opioid receptor and inhibiting noradrenaline reuptake. The efficacy of tapentadol is stated to be comparable to morphine and oxycodone. </p> </section> <section id="CD011460-sec-0002"> <h3 class="title" id="CD011460-sec-0002">Objectives</h3> <p>To assess the analgesic efficacy of tapentadol for the relief of cancer pain in adults, and the adverse events associated with its use in clinical trials. </p> </section> <section id="CD011460-sec-0003"> <h3 class="title" id="CD011460-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from January 2005 to July 2015, together with reference lists of retrieved papers and review articles, and two clinical trial registries. Searches started from 2005 because this covered the period during which clinical trials were conducted. We contacted the manufacturer of tapentadol in the UK to find additional trials not identified by electronic searches. We did not restrict searches by language. </p> </section> <section id="CD011460-sec-0004"> <h3 class="title" id="CD011460-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of tapentadol compared with placebo or active controls in adults with moderate to severe cancer pain. Pain had to be measured using a validated assessment tool, and studies had to include at least 10 participants per treatment arm. </p> </section> <section id="CD011460-sec-0005"> <h3 class="title" id="CD011460-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data using a standard form and assessed risk of bias. We extracted available data on study design, participant details, interventions, and outcomes, including analgesic outcome measures, withdrawals, and adverse events. </p> </section> <section id="CD011460-sec-0006"> <h3 class="title" id="CD011460-sec-0006">Main results</h3> <p>We included four studies with 1029 participants. All the studies used a parallel‐group design, and included an initial titration phase to determine the maximum effective and tolerated dose, followed by a maintenance phase. Tapentadol medication was taken twice daily and doses ranged from 50 to 500 mg per day. Rescue medication (morphine or oxycodone immediate‐release) was available to participants in all studies. </p> <p>Overall, 440 participants were randomised in classically designed RCTs, and 589 participants were enrolled in enriched‐enrolment, randomised‐withdrawal (EERW) trials. A total of 476 participants were randomised to titration with tapentadol and 338 participants took tapentadol throughout the maintenance phase of their trial. </p> <p>All studies used numerical rating scores, Patient Global Impression of Change scores, and use of rescue medication as measures of efficacy, and all reported on adverse events and withdrawals. </p> <p>All studies enrolled fewer than 200 participants per treatment arm and were therefore at risk of overestimating efficacy. One study was terminated early due to problems with supply of rescue medication, with fewer than 20 participants enrolled per treatment arm in the maintenance phase of the trial. We judged another study at high risk of bias due to an open‐label design. </p> <p>There were insufficient data for pooling and statistical analysis. Response rates for pain intensity were comparable across treatment groups in each study. In one EERW study, response rates were high across both treatment and placebo arms during the maintenance phase (62% tapentadol, 69% morphine, 50% placebo). For pain relief, tapentadol is no more and no less effective than oxycodone or morphine (low quality evidence). </p> <p>Treatment emergent adverse event rates were high, approximately 50% to 90%. The most common adverse events were gastrointestinal (nausea, vomiting, constipation) (low quality evidence). There was no advantage of tapentadol over morphine or oxycodone in terms of serious adverse events. The number of people experiencing effects on consciousness, appetite, or thirst was low. </p> </section> <section id="CD011460-sec-0007"> <h3 class="title" id="CD011460-sec-0007">Authors' conclusions</h3> <p>Information from RCTs on the effectiveness and tolerability of tapentadol was limited. The available studies were of moderate or small size and used different designs, which prevented pooling of data. Pain relief and adverse events were comparable between the tapentadol and morphine and oxycodone groups. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011460-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011460-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011460-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011460-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011460-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011460-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011460-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011460-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD011460-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011460-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011460-abs-0002" lang="en"> <h3>Oral tapentadol for cancer pain</h3> <p>Tapentadol taken by mouth produced good pain relief for people with moderate to severe cancer pain, similar to morphine or oxycodone. </p> <p>One person in two or three who gets cancer will experience moderate to severe pain. As the cancer advances, the pain may get worse. Morphine has been used since the 1950s for controlling cancer pain. Since then, a number of medications with morphine‐like actions have been developed for controlling pain, one of which is tapentadol. Tapentadol has been studied in clinical trials since 2005, but has only been used in the UK since 2011. It is available in tablets of different strengths, and is normally taken twice a day. In this review, we set out to estimate how well tapentadol worked and how many people had side effects, including serious effects or those that stopped people from taking the medication. </p> <p>We searched medical databases for clinical trials in adults with moderate to severe cancer pain that compared tapentadol with placebo (dummy medicine) or other pain‐relieving medicines, and measured pain using recognised assessment methods. </p> <p>We found four studies with 1029 participants. All four studies compared participants taking tapentadol to participants taking similar medicine, such as morphine or oxycodone. All studies gave participants a period of time to find the best dose to take, before continuing on the medication and comparing their pain levels. </p> <p>All the studies were small or medium sized, so the results are at risk of being influenced by random fluctuations rather than real differences, and they may also overestimate any effects. One trial allowed participants to know what medication they were taking, and one trial was stopped early due administrative problems, so they did not have enough people in the study. We have to be cautious interpreting results from these studies. </p> <p>Because the studies all used different designs, we could not compare the results from one with another. However, each study showed that there was not much difference between the pain levels of people taking tapentadol and people taking morphine and oxycodone. Pain levels were generally well controlled. The studies also showed there was no measurable difference in how many adverse effects people had while taking tapentadol, morphine, or oxycodone. </p> <p>Therefore, we can conclude only that the studies to date show tapentadol was no more or less effective and no more or less well tolerated than morphine and oxycodone. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011460-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011460-sec-0057"></div> <h3 class="title" id="CD011460-sec-0058">Implications for practice</h3> <section id="CD011460-sec-0058"> <section id="CD011460-sec-0059"> <h5 class="title">For people with cancer</h5> <p>There is little in this review to suggest that tapentadol should be considered above other opioids for the treatment of cancer‐related pain in terms of benefits or of harms. </p> </section> <section id="CD011460-sec-0060"> <h5 class="title">For clinicians</h5> <p>Current policies on the use of opioids, particularly morphine, do not need to be amended.</p> </section> <section id="CD011460-sec-0061"> <h5 class="title">For policy‐makers and funders</h5> <p>There is no persuasive evidence to amend existing cancer pain guidance to include tapentadol. Tapentadol may be worth trying if other medications have failed. </p> </section> </section> <h3 class="title" id="CD011460-sec-0062">Implications for research</h3> <section id="CD011460-sec-0062"> <section id="CD011460-sec-0063"> <h5 class="title">General</h5> <p>All opioids present challenges in terms of the risk:benefit ratio. Research should focus on finding better analgesics to manage cancer‐related pain. </p> </section> <section id="CD011460-sec-0064"> <h5 class="title">Design</h5> <p>Randomised controlled trials of large size, ideally at least 200 participants per treatment arm, using robust methods, and reporting clinically useful outcomes are needed to distinguish between different opioids to treat cancer‐related pain in terms of benefit, and particularly for adverse events. </p> </section> <section id="CD011460-sec-0065"> <h5 class="title">Measurement (endpoints)</h5> <p>A reduction of pain intensity of at least 50% should be included alongside other endpoints such as Patient Global Impression of Change for determining efficacy, and adverse event outcomes should take into account concerns about safety and serious adverse events. Data should be presented as the number of participants who respond. Mean data for pain relief are not acceptable. </p> </section> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011460-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011460-sec-0008"></div> <section id="CD011460-sec-0009"> <h3 class="title" id="CD011460-sec-0009">Description of the condition</h3> <p>Cancer is a common disease. There is a greater than 1 in 3 risk of developing cancer over a person's lifetime. In 2011 (the latest year for which statistics are available), approximately 331,000 people were diagnosed with cancer in the United Kingdom (UK), and the incidence is rising (<a href="./references#CD011460-bbs2-0005" title=" Cancer Research UK . Cancer incidence for all cancers combined. info.cancerresearchuk.org/cancerstats/incidence/all-cancers-combined/(accessed 7 September 2015).">Cancer Research UK</a>). Worldwide there were estimated to be around 14.1 million new cases of cancer in 2012, with incidence rates varying across the world (<a href="./references#CD011460-bbs2-0005" title=" Cancer Research UK . Cancer incidence for all cancers combined. info.cancerresearchuk.org/cancerstats/incidence/all-cancers-combined/(accessed 7 September 2015).">Cancer Research UK</a>). One review of the pharmacological management of cancer pain reported that 24% to 62% of adults have pain at the time of cancer diagnosis, and almost all patients will be in pain in the terminal stages of the disease (<a href="./references#CD011460-bbs2-0006" title="ClearyJF . The pharmacologic management of cancer pain. Journal of Palliative Medicine2007;10(6):1369-94. [DOI: 10.1089/jpm.2007.9842]">Cleary 2007</a>). Pain can be debilitating and have a serious impact on the quality of life. </p> </section> <section id="CD011460-sec-0010"> <h3 class="title" id="CD011460-sec-0010">Description of the intervention</h3> <p>Tapentadol is an opioid used to treat moderate to severe pain. It was first marketed in December 2010 in Australia, and in 2011 in the UK and United States of America (USA). Internationally, it is available as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg prolonged‐release tablets given 12‐hourly to a maximum of 500 mg daily for maintenance treatment; 50 mg and 75 mg immediate‐release (IR) tablets given four‐ to six‐hourly are available for acute pain and dose titration (<a href="./references#CD011460-bbs2-0021" title="DavisH . Tapentadol prolonged release. UKMI New Medicine Profile2011;(3):1-5.">UKMI 2011</a>). Tapentadol is a novel, centrally acting analgesic medicine, with an analgesic efficacy stated to be comparable to that of strong opioids such as oxycodone and morphine. It is both a μ‐opioid receptor agonist and noradrenaline reuptake inhibitor. It is a controlled drug under the Misuse of Drugs regulations in the UK, and a Schedule II controlled substance in the USA. A separate Cochrane review of tapentadol for chronic musculoskeletal pain is available (<a href="./references#CD011460-bbs2-0018" title="SantosJ , AlarcãoJ , FareleiraF , Vaz-CarneiroA , CostaJ . Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews2015, Issue 5. Art. No: CD009923. [DOI: 10.1002/14651858.CD009923.pub2]">Santos 2015</a>). </p> </section> <section id="CD011460-sec-0011"> <h3 class="title" id="CD011460-sec-0011">How the intervention might work</h3> <p>Tapentadol is purported to work by two different mechanisms: at opioid receptors and by inhibiting noradrenaline reuptake. Both mechanisms of action contribute to the analgesic activity and produce analgesia in a synergistic manner, such that relatively moderate activity at the two target sites is sufficient to produce a strong analgesic action (<a href="./references#CD011460-bbs2-0020" title="TzschentkeTM , ChristophT , KögelBY . The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs2014;29:319-29. [DOI: 10.1007/s40263-014-0151-9]">Tzschentke 2014</a>). </p> </section> <section id="CD011460-sec-0012"> <h3 class="title" id="CD011460-sec-0012">Why it is important to do this review</h3> <p>This review is one of a number of Cochrane reviews on the efficacy of strong analgesics for the relief of cancer‐related pain. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011460-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011460-sec-0013"></div> <p>To assess the analgesic efficacy of tapentadol for the relief of cancer pain in adults, and the adverse events associated with its use in clinical trials. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011460-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011460-sec-0014"></div> <section id="CD011460-sec-0015"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011460-sec-0016"> <h4 class="title">Types of studies</h4> <p> <ul id="CD011460-list-0001"> <li> <p>Randomised controlled trials (RCTs)</p> </li> <li> <p>Double‐blind studies, but we included single‐blind and open studies for inclusion as secondary evidence </p> </li> <li> <p>Placebo or active controls, or both</p> </li> <li> <p>Minimum of 10 participants per treatment arm</p> </li> </ul> </p> </section> <section id="CD011460-sec-0017"> <h4 class="title">Types of participants</h4> <p>Adult men and women aged 18 years and over, with cancer pain of moderate to severe intensity. </p> </section> <section id="CD011460-sec-0018"> <h4 class="title">Types of interventions</h4> <p>Oral tapentadol compared to placebo or active controls, in any dose, frequency, or duration of treatment. </p> </section> <section id="CD011460-sec-0019"> <h4 class="title">Types of outcome measures</h4> <p>Pain had to be measured using a validated assessment tool. For pain intensity, for example, this could be a 100 mm visual analogue scale (VAS) (no pain to worst pain imaginable) or a four‐point categorical scale (none, mild, moderate, severe), and for pain relief a 100 mm VAS (no relief to complete relief), or five‐point categorical scale (none, a little, some, a lot, complete or words to that effect). Measures of at least 30% (moderate) and at least 50% (substantial) reduction of pain over baseline are recommended outcomes for chronic pain studies from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) (<a href="./references#CD011460-bbs2-0008" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]">Dworkin 2008</a>). When considering Patient Global Impression of Change (PGIC), at least 30% reduction of pain over baseline equates to much improved or very much improved, and at least 50% to very much improved. </p> <section id="CD011460-sec-0020"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011460-list-0002"> <li> <p>Number of participants with pain reduction of ≥ 30% from baseline</p> </li> <li> <p>Number of participants with pain reduction of ≥ 50% from baseline</p> </li> <li> <p>Number of participants with pain no worse than mild</p> </li> <li> <p>Number of participants with PGIC of much improved or very much improved (or equivalent wording) </p> </li> </ul> </p> </section> <section id="CD011460-sec-0021"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011460-list-0003"> <li> <p>Quality of life measures</p> </li> <li> <p>Use of rescue medication</p> </li> <li> <p>Participant satisfaction or preference</p> </li> <li> <p>Adverse events: any, serious</p> </li> <li> <p>Attrition: withdrawals due to lack of efficacy or adverse events (including death)</p> </li> </ul> </p> </section> </section> </section> <section id="CD011460-sec-0022"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011460-sec-0023"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases.</p> <p> <ul id="CD011460-list-0004"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL, via CRSO; to 28 July 2015). </p> </li> <li> <p>MEDLINE (via Ovid; 2005 to 28 July 2015).</p> </li> <li> <p>EMBASE (via Ovid; 2005 to 28 July 2015).</p> </li> </ul> </p> <p>Searches started from 2005 because this covered the period during which clinical trials were conducted. </p> </section> <section id="CD011460-sec-0024"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of all included studies and any relevant reviews. We also searched two clinical trial registers (<a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>)) to identify additional published or unpublished data. </p> <p>We contacted the manufacturer of tapentadol in the UK to find additional trials not identified by electronic searches. </p> <section id="CD011460-sec-0025"> <h5 class="title">Language</h5> <p>We did not restrict searches or inclusion by language.</p> </section> </section> </section> <section id="CD011460-sec-0026"> <h3 class="title" id="CD011460-sec-0026">Data collection and analysis</h3> <section id="CD011460-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently read the titles and abstracts of all studies identified by the searches, and excluded those that clearly did not meet the inclusion criteria. For the remaining studies, we read the full manuscripts to assess whether they should be included. We resolved any discrepancies between review authors by discussion; where necessary, we consulted a third review author. We did not anonymise studies before selection. </p> </section> <section id="CD011460-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data using a standard form and agreed on the data before entry into Review Manager 5 software (<a href="./references#CD011460-bbs2-0017" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We extracted information about the number of participants treated and demographic details, type of cancer, drug and dosing regimen, study design (placebo or active control) and methods, study duration and follow‐up, analgesic outcome measures and results, withdrawals, and adverse events. </p> </section> <section id="CD011460-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011460-bbs2-0009" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>), and adapted from those used by the Cochrane Pregnancy and Childbirth Group. We resolved any disagreements by discussion. We assessed the following for each included study. </p> <p> <ul id="CD011460-list-0005"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, for example random number table; computer random number generator); unclear risk of bias (when the method used to generate sequence was not clearly stated). We excluded studies at high risk of bias that used a non‐random process (for example, odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (for example, telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (when the method was not clearly stated). We excluded studies that did not conceal allocation and were therefore at a high risk of bias (for example, open list). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, for example, identical tablets; matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved); high risk of bias (study was not double‐blind). </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (fewer than 10% of participants did not complete the study or used 'baseline observation carried forward' (BOCF) analysis, or both); unclear risk of bias (used 'last observation carried forward' (LOCF) analysis); high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (≥ 200 participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (&lt; 50 participants per treatment arm) </p> </li> </ul> </p> </section> <section id="CD011460-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to use dichotomous data to calculate risk ratios (RR) with 95% confidence intervals (CI), and calculated numbers needed to treat for an additional beneficial outcome (NNT) and the number needed to treat for an additional harmful outcome (NNH) as the reciprocal of the absolute risk reduction (<a href="./references#CD011460-bbs2-0011" title="McQuayH , MooreR . An Evidence-based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0-19-263048-2]">McQuay 1998</a>). In the event, there were insufficient data for statistical analysis. </p> <p>If there had been sufficient data, we would have used the following terms to describe adverse outcomes in terms of harm or prevention of harm. </p> <p> <ul id="CD011460-list-0006"> <li> <p>When significantly fewer adverse outcomes occurred with tapentadol compared with control (placebo or active), we planned to use the term 'number needed to treat to prevent one event' (NNTp). </p> </li> <li> <p>When significantly more adverse outcomes occurred with tapentadol compared with control (placebo or active), we planned to use the term 'number needed to harm or cause one event' (NNH). </p> </li> </ul> </p> <p>We did not plan to use continuous data for the primary outcome because it is inappropriate where there is an underlying skewed distribution, as is usually the case with analgesic response. </p> </section> <section id="CD011460-sec-0031"> <h4 class="title">Dealing with missing data</h4> <p>We planned to use intention‐to‐treat (ITT) analysis, including participants who were randomised, took the study medication, and gave a minimum of one post‐baseline assessment. Where there were missing participants or information, we planned to assign them to a zero improvement category where possible. We also looked for information about how data from withdrawals and drop‐outs were handled. In original studies, participants may have been analysed using LOCF (that is, their level of pain when stopping the medication) or BOCF (that is, returned to their baseline observation). </p> <p>Where there were substantial numbers (&gt; 10%) of participants missing from analyses, we have commented. </p> </section> <section id="CD011460-sec-0032"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess statistical heterogeneity using L'Abbé plots, a visual method for assessing differences in results of individual studies (<a href="./references#CD011460-bbs2-0010" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta-analysis in clinical research. Annals of Internal Medicine1987;107(2):224-33.">L'Abbé 1987</a>), and by using the I<sup>2</sup> statistic. We anticipated that there could be an effect of differences between participants, environment (inpatient versus outpatient), and outcome measures. We planned to explore these with sensitivity analyses where there were sufficient data. In the event, there were insufficient data for statistical analysis. </p> </section> <section id="CD011460-sec-0033"> <h4 class="title">Assessment of reporting biases</h4> <p>The aim of this review was to use dichotomous data of known utility (<a href="./references#CD011460-bbs2-0014" title="MooreRA , MooreOA , DerryS , PelosoPM , GammaitoniAR , WangH . Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805]">Moore 2010</a>; <a href="./references#CD011460-bbs2-0015" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12. [DOI: 10.1111/anae.12148]">Moore 2013</a>). The review did not depend on what authors of the original studies chose to report or not. </p> <p>We planned to assess publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNT of 10 or higher) (<a href="./references#CD011460-bbs2-0013" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: MooreRA , KalsoE , McQuayHJ , editors(s). Systematic Reviews in Pain Research: Methodology Refined. 1st edition. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0931092695]">Moore 2008</a>). In the event, there were insufficient data for statistical analysis. </p> </section> <section id="CD011460-sec-0034"> <h4 class="title">Data synthesis</h4> <p>We planned to carry out data synthesis and statistical analysis using Review Manager 5 software (<a href="./references#CD011460-bbs2-0017" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). Where appropriate, we would have pooled data for each dichotomous outcome and calculated RRs with 95% CIs using the fixed‐effect model (<a href="./references#CD011460-bbs2-0016" title="MorrisJA , GardnerMJ . Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: GardnerMJ , AltmanDG , editors(s). Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London: BMJ Books, 1995:50-63.">Morris 1995</a>), together with NNTs with 95% CIs (<a href="./references#CD011460-bbs2-0007" title="CookRJ , SackettDL . The number needed to treat: a clinically useful measure of treatment effect. BMJ1995;310(6977):452-4.">Cook 1995</a>). We would have assumed a statistically significant benefit of active treatment over control when the lower limit of the 95% CI of the RR was greater than one, and of control over active treatment when the upper limit of the 95% CI was less than one. We planned to calculate RR and NNH for adverse outcomes in the same way. </p> <p>We planned to analyse studies carried out under double‐blind conditions separately from those that were not, and not to carry out pooled analysis where there were fewer than 200 participants in the comparison (<a href="./references#CD011460-bbs2-0012" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]">Moore 1998</a>). In the event, there were insufficient data for statistical analysis. </p> <p>We intended to test for statistically significant differences between subgroups using the z test (<a href="./references#CD011460-bbs2-0019" title="TramèrMR , ReynoldsDJ , MooreRA , McQuayHJ . Impact of covert duplicate publication on meta-analysis: a case study. BMJ1997;315(7109):635-40.">Tramèr 1997</a>); however, data were insufficient. </p> </section> <section id="CD011460-sec-0035"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not plan to carry out subgroup analysis because were aware that the evidence base was small. </p> <p>Different doses were not considered because participants were titrated to effective dose. </p> </section> <section id="CD011460-sec-0036"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analyses for duration of study, age of participants (&lt; 18 years versus ≥ 18 years), and setting (inpatient versus outpatient), but there were insufficient data for analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011460-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011460-sec-0037"></div> <section id="CD011460-sec-0038"> <h3 class="title">Description of studies</h3> <section id="CD011460-sec-0039"> <h4 class="title">Results of the search</h4> <p>Searches identified 60 potentially relevant studies in CENTRAL, 16 in MEDLINE, and 133 in EMBASE. We also identified six studies in <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>. After screening titles and abstracts, we read three studies and four clinical trial records in full (<a href="#CD011460-fig-0001">Figure 1</a>). The records in <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> provided useful data on adverse events that were not available in the published studies. </p> <div class="figure" id="CD011460-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011460-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/image_n/nCD011460-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We identified no additional studies through contacting the manufacturer.</p> </section> <section id="CD011460-sec-0040"> <h4 class="title">Included studies</h4> <p>We included four studies (eight reports) with 1029 participants (<a href="./references#CD011460-bbs2-0001" title="ImanakaK , TominagaY , EtropolskiM , Van HoveI , OhsakaM , WanibeM , et al. Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain. Current Medical Research and Opinion2014;30(9):1909-10. [DOI: 10.1185/03007995.2014.919909]ImanakaK , TominagaY , EtropolskiM , vanHoveI , OhsakaM , WanibeM , et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Current Medical Research and Opinion2013;29(10):1399-409. [DOI: 10.1185/03007995.2013.831816]Janssen Research and Development, LLC. A safety and efficacy study of JNS024 extended release (ER) in Japanese and Korean patients with chronic malignant tumor-related cancer pain. www.clinicaltrials.gov/ct2/show/NCT01165281 (accessed 14 January 2015)2013. [CTG: NCT01165281]">Imanaka 2013</a>; <a href="./references#CD011460-bbs2-0002" title="ImanakaK , TominagaY , EtropolskiM , OhashiH , HiroseK , MatsumuraT . Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clinical Drug Investigation2014;34(7):501-11. [DOI: 10.1007/s40261-014-0204-3] [Clinicaltrials.gove identifier: NCT01309386]Janssen PharmaceuticalKK . A safety and efficacy study of oral tapentadol extended-release in Japanese participants. www.clinicaltrials.gov/ct2/show/NCT01309386 (accessed 14 January 2015)2013. [CTG: NCT01309386]">Imanaka 2014</a>; <a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a>; <a href="./references#CD011460-bbs2-0004" title="Poulin P (principal investigator). A study to evaluate the effectiveness and safety of CG5503 (tapentadol) in the treatment of chronic tumor-related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00505414 (accessed 14 January 2015)2010. [CTG: NCT00505414]">NCT00505414</a>). All the studies enrolled participants with chronic malignant tumour‐related pain who were experiencing pain intensities of at least 4/10 with current treatment. The mean age was 60 to 65 years, with most participants aged 50 to 75 years. </p> <p>All the studies included an initial titration phase to determine the maximum effective and tolerated dose. Medication was taken twice daily. Starting doses were dependent on previous opioid exposure and were as low as 25 mg twice daily for participants who had not taken opioids in the previous 28 days in <a href="./references#CD011460-bbs2-0001" title="ImanakaK , TominagaY , EtropolskiM , Van HoveI , OhsakaM , WanibeM , et al. Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain. Current Medical Research and Opinion2014;30(9):1909-10. [DOI: 10.1185/03007995.2014.919909]ImanakaK , TominagaY , EtropolskiM , vanHoveI , OhsakaM , WanibeM , et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Current Medical Research and Opinion2013;29(10):1399-409. [DOI: 10.1185/03007995.2013.831816]Janssen Research and Development, LLC. A safety and efficacy study of JNS024 extended release (ER) in Japanese and Korean patients with chronic malignant tumor-related cancer pain. www.clinicaltrials.gov/ct2/show/NCT01165281 (accessed 14 January 2015)2013. [CTG: NCT01165281]">Imanaka 2013</a>, but 100 mg twice daily in opioid naïve participants in <a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a> and <a href="./references#CD011460-bbs2-0004" title="Poulin P (principal investigator). A study to evaluate the effectiveness and safety of CG5503 (tapentadol) in the treatment of chronic tumor-related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00505414 (accessed 14 January 2015)2010. [CTG: NCT00505414]">NCT00505414</a>. Maximum doses were 200 to 250 mg twice daily. </p> <p>Rescue medication was available to participants in all studies; three studies used IR morphine as rescue medication for all treatment groups, and one study used an IR form of either morphine or oxycodone, with doses varying from morphine IR 5 mg or oxycodone IR 2.5 mg to a dose equivalent to one‐sixth of total daily opioid dose. All studies used pain intensity numerical rating scores (NRS), PGIC scores, and use of rescue medication as primary outcome measures. </p> <p>All the studies were randomised and used a parallel‐group design, but otherwise their methods were different. Study size varied from 93 to 496 participants. </p> <p>No studies reported on quality of life, quantities of rescue medication used, or participant satisfaction or preference. </p> <p><a href="./references#CD011460-bbs2-0001" title="ImanakaK , TominagaY , EtropolskiM , Van HoveI , OhsakaM , WanibeM , et al. Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain. Current Medical Research and Opinion2014;30(9):1909-10. [DOI: 10.1185/03007995.2014.919909]ImanakaK , TominagaY , EtropolskiM , vanHoveI , OhsakaM , WanibeM , et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Current Medical Research and Opinion2013;29(10):1399-409. [DOI: 10.1185/03007995.2013.831816]Janssen Research and Development, LLC. A safety and efficacy study of JNS024 extended release (ER) in Japanese and Korean patients with chronic malignant tumor-related cancer pain. www.clinicaltrials.gov/ct2/show/NCT01165281 (accessed 14 January 2015)2013. [CTG: NCT01165281]">Imanaka 2013</a> was a four‐week (including titration) double‐blind, active‐controlled study of tapentadol extended‐release (ER) with oxycodone controlled‐release (CR). </p> <p><a href="./references#CD011460-bbs2-0002" title="ImanakaK , TominagaY , EtropolskiM , OhashiH , HiroseK , MatsumuraT . Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clinical Drug Investigation2014;34(7):501-11. [DOI: 10.1007/s40261-014-0204-3] [Clinicaltrials.gove identifier: NCT01309386]Janssen PharmaceuticalKK . A safety and efficacy study of oral tapentadol extended-release in Japanese participants. www.clinicaltrials.gov/ct2/show/NCT01309386 (accessed 14 January 2015)2013. [CTG: NCT01309386]">Imanaka 2014</a> was a four‐week open‐label, active‐controlled, dose‐titration study using tapentadol ER and morphine sustained‐release (SR). </p> <p><a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a> was an enriched‐enrolment, randomised‐withdrawal, active‐ and placebo‐controlled, double‐blind efficacy trial. It had a two‐week titration phase (tapentadol ER or morphine SR) and four‐week maintenance phase (tapentadol ER or placebo, or morphine SR). </p> <p><a href="./references#CD011460-bbs2-0004" title="Poulin P (principal investigator). A study to evaluate the effectiveness and safety of CG5503 (tapentadol) in the treatment of chronic tumor-related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00505414 (accessed 14 January 2015)2010. [CTG: NCT00505414]">NCT00505414</a> used a similar design to <a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a>. This study was terminated early due to a recall of the morphine rescue medication and issues regarding supply of an alternative. Only 93 of the planned 573 participants were available for analysis. </p> <p>Full details are in the <a href="./references#CD011460-sec-0085" title="">Characteristics of included studies</a> table. CR, SR, and ER are equivalent terms for formulations designed to provide prolonged effects while maintaining relatively constant drug levels that are within a 'safe' therapeutic window. </p> </section> <section id="CD011460-sec-0041"> <h4 class="title">Excluded studies</h4> <p>We did not exclude any studies after reading the full text. Two of the clinical trial reports related to non‐randomised studies. </p> </section> </section> <section id="CD011460-sec-0042"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD011460-sec-0043"> <h4 class="title">Allocation</h4> <p>All the studies stated that they were randomised, and three reported adequate methods of sequence generation and allocation concealment (<a href="./references#CD011460-bbs2-0001" title="ImanakaK , TominagaY , EtropolskiM , Van HoveI , OhsakaM , WanibeM , et al. Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain. Current Medical Research and Opinion2014;30(9):1909-10. [DOI: 10.1185/03007995.2014.919909]ImanakaK , TominagaY , EtropolskiM , vanHoveI , OhsakaM , WanibeM , et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Current Medical Research and Opinion2013;29(10):1399-409. [DOI: 10.1185/03007995.2013.831816]Janssen Research and Development, LLC. A safety and efficacy study of JNS024 extended release (ER) in Japanese and Korean patients with chronic malignant tumor-related cancer pain. www.clinicaltrials.gov/ct2/show/NCT01165281 (accessed 14 January 2015)2013. [CTG: NCT01165281]">Imanaka 2013</a>; <a href="./references#CD011460-bbs2-0002" title="ImanakaK , TominagaY , EtropolskiM , OhashiH , HiroseK , MatsumuraT . Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clinical Drug Investigation2014;34(7):501-11. [DOI: 10.1007/s40261-014-0204-3] [Clinicaltrials.gove identifier: NCT01309386]Janssen PharmaceuticalKK . A safety and efficacy study of oral tapentadol extended-release in Japanese participants. www.clinicaltrials.gov/ct2/show/NCT01309386 (accessed 14 January 2015)2013. [CTG: NCT01309386]">Imanaka 2014</a>; <a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a>). The online clinical trial summary of the remaining study did not report details of the sequence generation or allocation process, although it is likely that this was adequate (<a href="./references#CD011460-bbs2-0004" title="Poulin P (principal investigator). A study to evaluate the effectiveness and safety of CG5503 (tapentadol) in the treatment of chronic tumor-related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00505414 (accessed 14 January 2015)2010. [CTG: NCT00505414]">NCT00505414</a>). </p> </section> <section id="CD011460-sec-0044"> <h4 class="title">Blinding</h4> <p>Two studies adequately reported the methods used to maintain blinding of participants and study personnel (<a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a>; <a href="./references#CD011460-bbs2-0004" title="Poulin P (principal investigator). A study to evaluate the effectiveness and safety of CG5503 (tapentadol) in the treatment of chronic tumor-related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00505414 (accessed 14 January 2015)2010. [CTG: NCT00505414]">NCT00505414</a>), and one did not report details of the method (<a href="./references#CD011460-bbs2-0001" title="ImanakaK , TominagaY , EtropolskiM , Van HoveI , OhsakaM , WanibeM , et al. Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain. Current Medical Research and Opinion2014;30(9):1909-10. [DOI: 10.1185/03007995.2014.919909]ImanakaK , TominagaY , EtropolskiM , vanHoveI , OhsakaM , WanibeM , et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Current Medical Research and Opinion2013;29(10):1399-409. [DOI: 10.1185/03007995.2013.831816]Janssen Research and Development, LLC. A safety and efficacy study of JNS024 extended release (ER) in Japanese and Korean patients with chronic malignant tumor-related cancer pain. www.clinicaltrials.gov/ct2/show/NCT01165281 (accessed 14 January 2015)2013. [CTG: NCT01165281]">Imanaka 2013</a>). The remaining study was an open‐label study during which participants were switched from one treatment to another (<a href="./references#CD011460-bbs2-0002" title="ImanakaK , TominagaY , EtropolskiM , OhashiH , HiroseK , MatsumuraT . Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clinical Drug Investigation2014;34(7):501-11. [DOI: 10.1007/s40261-014-0204-3] [Clinicaltrials.gove identifier: NCT01309386]Janssen PharmaceuticalKK . A safety and efficacy study of oral tapentadol extended-release in Japanese participants. www.clinicaltrials.gov/ct2/show/NCT01309386 (accessed 14 January 2015)2013. [CTG: NCT01309386]">Imanaka 2014</a>); we judged this study at high risk of bias. </p> </section> <section id="CD011460-sec-0045"> <h4 class="title">Incomplete outcome data</h4> <p>There were several minor discrepancies between the text and the tables or figures in the published studies, and between published results and the online clinical trial summaries. We considered that these were unlikely to change our conclusions substantially, given the already small amount of data and uncertainties about any treatment effects. </p> </section> <section id="CD011460-sec-0046"> <h4 class="title">Other potential sources of bias</h4> <p>None of the included studies enrolled 200 or more participants per treatment arm, which we consider is the minimum required to give confidence in the results. Three studies enrolled between 50 and 199 participants per treatment arm (<a href="./references#CD011460-bbs2-0001" title="ImanakaK , TominagaY , EtropolskiM , Van HoveI , OhsakaM , WanibeM , et al. Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain. Current Medical Research and Opinion2014;30(9):1909-10. [DOI: 10.1185/03007995.2014.919909]ImanakaK , TominagaY , EtropolskiM , vanHoveI , OhsakaM , WanibeM , et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Current Medical Research and Opinion2013;29(10):1399-409. [DOI: 10.1185/03007995.2013.831816]Janssen Research and Development, LLC. A safety and efficacy study of JNS024 extended release (ER) in Japanese and Korean patients with chronic malignant tumor-related cancer pain. www.clinicaltrials.gov/ct2/show/NCT01165281 (accessed 14 January 2015)2013. [CTG: NCT01165281]">Imanaka 2013</a>; <a href="./references#CD011460-bbs2-0002" title="ImanakaK , TominagaY , EtropolskiM , OhashiH , HiroseK , MatsumuraT . Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clinical Drug Investigation2014;34(7):501-11. [DOI: 10.1007/s40261-014-0204-3] [Clinicaltrials.gove identifier: NCT01309386]Janssen PharmaceuticalKK . A safety and efficacy study of oral tapentadol extended-release in Japanese participants. www.clinicaltrials.gov/ct2/show/NCT01309386 (accessed 14 January 2015)2013. [CTG: NCT01309386]">Imanaka 2014</a>; <a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a>), where the effects of size are unknown. One study was terminated early and enrolled fewer than 50 participants per treatment arm (<a href="./references#CD011460-bbs2-0004" title="Poulin P (principal investigator). A study to evaluate the effectiveness and safety of CG5503 (tapentadol) in the treatment of chronic tumor-related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00505414 (accessed 14 January 2015)2010. [CTG: NCT00505414]">NCT00505414</a>). We judged this study to be potentially at high risk of bias. </p> <p><a href="#CD011460-fig-0002">Figure 2</a> and <a href="#CD011460-fig-0003">Figure 3</a> show a graphical representation. </p> <div class="figure" id="CD011460-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011460-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/image_n/nCD011460-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011460-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011460-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/image_n/nCD011460-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> </section> <section id="CD011460-sec-0047"> <h3 class="title" id="CD011460-sec-0047">Effects of interventions</h3> <section id="CD011460-sec-0048"> <h4 class="title">Effect on pain</h4> <p><a href="./references#CD011460-bbs2-0001" title="ImanakaK , TominagaY , EtropolskiM , Van HoveI , OhsakaM , WanibeM , et al. Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain. Current Medical Research and Opinion2014;30(9):1909-10. [DOI: 10.1185/03007995.2014.919909]ImanakaK , TominagaY , EtropolskiM , vanHoveI , OhsakaM , WanibeM , et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Current Medical Research and Opinion2013;29(10):1399-409. [DOI: 10.1185/03007995.2013.831816]Janssen Research and Development, LLC. A safety and efficacy study of JNS024 extended release (ER) in Japanese and Korean patients with chronic malignant tumor-related cancer pain. www.clinicaltrials.gov/ct2/show/NCT01165281 (accessed 14 January 2015)2013. [CTG: NCT01165281]">Imanaka 2013</a> was a four‐week (including titration) double‐blind study of 340 Japanese and Korean participants. The majority of participants (&gt; 92%) had metastatic cancers. Those recruited were not satisfied with their current pain management and after screening were randomised to receive either tapentadol ER at 25 to 200 mg twice daily or oxycodone CR at 5 to 40 mg daily. </p> <p>The study did not report our primary outcome of no worse than mild pain.</p> <p>Mean pain intensity was assessed once daily using an 11‐point NRS. For tapentadol 63/168, and for oxycodone 59/172, participants achieved a reduction in pain intensity of at least 50%. For tapentadol 80/168 and for oxycodone 82/172, participants achieved a reduction in pain intensity of at least 30%. Using PGIC at the level of 'much or very much improved', this was achieved by 74/168 participants in the tapentadol group and 70/172 participants in the oxycodone group, and for 'very much improved' the numbers were 22/168 for tapentadol and 17/172 for oxycodone. </p> <p><a href="./references#CD011460-bbs2-0002" title="ImanakaK , TominagaY , EtropolskiM , OhashiH , HiroseK , MatsumuraT . Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clinical Drug Investigation2014;34(7):501-11. [DOI: 10.1007/s40261-014-0204-3] [Clinicaltrials.gove identifier: NCT01309386]Janssen PharmaceuticalKK . A safety and efficacy study of oral tapentadol extended-release in Japanese participants. www.clinicaltrials.gov/ct2/show/NCT01309386 (accessed 14 January 2015)2013. [CTG: NCT01309386]">Imanaka 2014</a> was a four‐week open‐label, active‐controlled, dose‐titration study in 100 Japanese participants with chronic malignant tumour‐related pain. In this case, participants were converted from other opioid medicines (oxycodone, morphine, or fentanyl) using a ratio of 10:2 for oxycodone, 10:3 for morphine, and 10:0.03 for fentanyl. Participants were randomised to receive either tapentadol ER at 100 to 500 mg daily, or morphine CR at 20 to 140 mg daily. </p> <p>The study did not report our primary outcomes of ≥ 30% and ≥ 50% pain reduction, or no worse than mild pain. </p> <p>Pain intensity was assessed as an average score once a day using an 11‐point NRS. For tapentadol 42/50, and for morphine 49/50, participants maintained pain control comparable with pre‐study levels. Investigators also assessed PGIC, but as these participants started the study with good pain relief, the results were low and not meaningful. </p> <p><a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a> was an enriched‐enrolment study conducted in 16 countries. A total of 496 participants were either opioid naive or dissatisfied with their current opioid therapy and presented with a pain intensity of &gt; 5/10. Participants were titrated to an optimal dose using either tapentadol ER or morphine CR over two weeks. Participants who completed this phase and were stable with a mean pain intensity of &lt; 5/10 were moved into the maintenance phase (a period of stable dose after titration). Participants receiving morphine continued on the same dose as before while participants receiving tapentadol were randomised to either tapentadol or placebo. Oral morphine sulphate IR was available as a rescue medication with no maximum dose. </p> <p>The study did not report our primary outcomes of ≥ 30% and ≥ 50% pain reduction and no worse than mild pain. PGIC was reported only in the ClinicalTrials.gov record (NCT00472303, see <a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a>). PGIC much and very much improved at the end of the maintenance phase was reported by 33/94 participants with tapentadol, 29/97 with morphine, and 37/103 with placebo. PGIC very much improved at the end of the maintenance phase was reported by 4/94 participants with tapentadol, 6/97 with morphine, and 6/103 with placebo. </p> <p>Response was assessed by pain intensity, but also a measure of rescue medication use and a measure of treatment adherence linked to tolerability. Responders had pain intensity &lt; 5/10 (≤ moderate pain), used a mean morphine dose of &lt; 20 mg daily, and remained in the study for the whole 28 days. Due to the complex design of this study and because we were unable to perform a meta‐analysis, we have reported per‐protocol data. In the titration phase, 174/229 participants with tapentadol and 83/100 with morphine achieved a pain intensity score of &lt; 5. In the maintenance phase, the numbers of responders were 65/105 participants with tapentadol, 75/109 with morphine, and 55/111 with placebo. </p> <p><a href="./references#CD011460-bbs2-0004" title="Poulin P (principal investigator). A study to evaluate the effectiveness and safety of CG5503 (tapentadol) in the treatment of chronic tumor-related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00505414 (accessed 14 January 2015)2010. [CTG: NCT00505414]">NCT00505414</a> used a similar design to <a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a>. This study was terminated early but limited results were available on the <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> website. Only 93 of the planned 573 participants were available for analysis. </p> <p>The study did not report our primary outcomes of ≥ 30% and ≥ 50% pain reduction, or no worse than mild pain. PGIC much and very much improved at the end of the maintenance phase was reported by 8/15 participants with tapentadol, 4/13 with morphine, and 2/9 with placebo. PGIC very much improved at the end of the maintenance phase was reported by 0/15 participants with tapentadol, 1/13 with morphine, and 0/9 with placebo. </p> <p>Compared with <a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a>, responders could have up to 30 mg morphine IR rescue medication per day on average. The maintenance phase enrolled fewer than 20 participants per group. Responders in the maintenance phase were recorded as 8/15 participants with tapentadol, 6/18 with morphine, and 3/14 with placebo. </p> </section> <section id="CD011460-sec-0049"> <h4 class="title">Adverse events</h4> <p><a href="./references#CD011460-bbs2-0001" title="ImanakaK , TominagaY , EtropolskiM , Van HoveI , OhsakaM , WanibeM , et al. Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain. Current Medical Research and Opinion2014;30(9):1909-10. [DOI: 10.1185/03007995.2014.919909]ImanakaK , TominagaY , EtropolskiM , vanHoveI , OhsakaM , WanibeM , et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Current Medical Research and Opinion2013;29(10):1399-409. [DOI: 10.1185/03007995.2013.831816]Janssen Research and Development, LLC. A safety and efficacy study of JNS024 extended release (ER) in Japanese and Korean patients with chronic malignant tumor-related cancer pain. www.clinicaltrials.gov/ct2/show/NCT01165281 (accessed 14 January 2015)2013. [CTG: NCT01165281]">Imanaka 2013</a> reported that treatment‐emergent adverse events were similar in both groups with approximately 90% of participants experiencing such an event. The most common events were gastrointestinal: nausea, vomiting, or constipation. The rates were 55% (93/168) with tapentadol and 67% (116/172) with oxycodone. These events were most common in week one and were similar irrespective of gender, age, or initial pain intensity. Adverse events leading to treatment withdrawal were experienced by 13% (22/168) of participants with tapentadol and 17% (29/172) with oxycodone. Somnolence occurred in 17% (29/168) of participants with tapentadol and 20% (36/172) with oxycodone. Delirium was reported by 6/168 participants with tapentadol and 6/172 with oxycodone based on the ClinicalTrials.gov record for this study. </p> <p>In addition, 21/168 participants taking tapentadol and 24/172 taking oxycodone reported a decrease in appetite. Just one participant in each group reported dehydration (based on ClinicalTrials.gov record). </p> <p><a href="./references#CD011460-bbs2-0002" title="ImanakaK , TominagaY , EtropolskiM , OhashiH , HiroseK , MatsumuraT . Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clinical Drug Investigation2014;34(7):501-11. [DOI: 10.1007/s40261-014-0204-3] [Clinicaltrials.gove identifier: NCT01309386]Janssen PharmaceuticalKK . A safety and efficacy study of oral tapentadol extended-release in Japanese participants. www.clinicaltrials.gov/ct2/show/NCT01309386 (accessed 14 January 2015)2013. [CTG: NCT01309386]">Imanaka 2014</a> reported that treatment‐emergent adverse events were similar in both groups with approximately 90% of participants experiencing such an event, the percentage was slightly higher in the cohort aged over 65 years. The most common events were gastrointestinal: nausea, vomiting, or constipation. The rates were 38% (19/50) with tapentadol and 54% (27/50) with morphine. These events were most common in week one. Adverse events leading to treatment withdrawal were experienced by 28% (14/50) of participants with tapentadol and 38% (19/50) with morphine. Somnolence occurred in 16% (8/50) of participants with tapentadol and delirium was recorded for 1/50 participants with morphine. </p> <p>One participant in the morphine group reported weight loss, one participant in each group reported a decrease in appetite, and 2/50 participants with tapentadol and 1/50 with morphine reported stomatitis. </p> <p><a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a> reported that treatment‐emergent adverse events were recorded in 50% of the tapentadol group and 64% of the morphine group during the titration phase. The most common events were gastrointestinal: nausea, vomiting, or constipation. The rates were 30% (100/338) with tapentadol and 47% (74/158) with morphine. During the maintenance phase, the number of participants experiencing treatment‐emergent adverse events remained high, at about 60% for all groups: 66/106 participants with tapentadol, 68/109 with morphine, and 63/112 with placebo. The number experiencing gastrointestinal events was 25% to 30% (24/106 participants with tapentadol, 25/109 with morphine, and 28/112 with placebo). Adverse events leading to treatment withdrawal occurred in about 8% of participants in the titration phase for both tapentadol (28/338) and morphine (12/158), and 5% in the maintenance phase for all three treatment groups (5/106 participants with tapentadol, 6/109 with morphine, and 6/112 with placebo). Somnolence occurred in 3% (3/106) of participants with tapentadol and 5% (3/109) with morphine, and delirium was not reported. </p> <p>In the maintenance phase, dry mouth was reported by 3/106 participants with tapentadol, 1/109 with morphine, and 2/112 with placebo. A decreased appetite was reported for 8/106 participants with tapentadol, 6/109 with morphine, and 6/112 with placebo. </p> <p><a href="./references#CD011460-bbs2-0004" title="Poulin P (principal investigator). A study to evaluate the effectiveness and safety of CG5503 (tapentadol) in the treatment of chronic tumor-related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00505414 (accessed 14 January 2015)2010. [CTG: NCT00505414]">NCT00505414</a> reported that treatment‐emergent adverse events were recorded in 63% of the tapentadol group and 80% of the morphine group. The most common events were gastrointestinal: nausea, vomiting, or constipation. The rates were 48% (29/62) participants with tapentadol and 61% (19/31) with morphine. Adverse events leading to treatment withdrawal were low in all groups. Somnolence occurred in 3% (2/62) of participants with tapentadol and 6% (2/31) with morphine, and delirium was not reported. </p> <p>Dry mouth was reported for one participant in the placebo group and thirst by one in the morphine group. There were three cases of anorexia: two in the morphine group and one in the placebo group. </p> </section> <section id="CD011460-sec-0050"> <h4 class="title">Withdrawals</h4> <p>Withdrawals due to adverse events, lack of efficacy, death, or other reasons are described in <a href="./appendices#CD011460-sec-0068">Appendix 1</a>. There was no evidence of a difference between tapentadol, oxycodone, morphine, or placebo for any cause of withdrawal. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011460-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011460-sec-0051"></div> <section id="CD011460-sec-0052"> <h3 class="title" id="CD011460-sec-0052">Summary of main results</h3> <p>For pain relief these studies show that tapentadol is as effective as oxycodone or morphine in the comparator studies. However, there is no evidence that tapentadol is superior (low quality evidence). There were two enriched‐enrolment randomised‐withdrawal studies (<a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a>; <a href="./references#CD011460-bbs2-0004" title="Poulin P (principal investigator). A study to evaluate the effectiveness and safety of CG5503 (tapentadol) in the treatment of chronic tumor-related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00505414 (accessed 14 January 2015)2010. [CTG: NCT00505414]">NCT00505414</a>), the second of which was terminated early due to supply problems with the rescue medication. In the <a href="./references#CD011460-bbs2-0003" title="Kress HG (principal investigator). A study to evaluate tapentadol (CG5503) in the treatment of chronic tumor related pain compared with placebo and morphine. www.clinicaltrials.gov/ct2/show/NCT00472303 (accessed 14 January 2015)2014. [CTG: NCT00472303]KressHG , KochED , KosturskiH , SteupA , KarcherK , DoganC , et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. European Journal of Pain2016;20(9):1513-8. [DOI: 10.1002/ejp.875]KressHG , KochED , KosturskiH , SteupA , KarcherK , LangeB , et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician2014;17(4):329-43. [PMID: 25054392]">Kress 2014</a> study, the response rates during the double‐blind withdrawal phase were high in all groups including the placebo arm. We note that entry criteria included a pain intensity of greater than 5/10 and that for response, a pain intensity of less than 5/10 was required. We anticipate that such a small improvement is readily obtainable. </p> <p>There was no advantage of tapentadol over morphine or oxycodone in terms of serious adverse events in these studies (very low quality evidence). </p> <p>In a previous review we examined the impact of four opioids on patient consciousness, appetite, and thirst (<a href="./references#CD011460-bbs2-0022" title="WiffenPJ , DerryS , MooreRA . Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD011056. [DOI: 10.1002/14651858.CD011056.pub2]">Wiffen 2014</a>). These symptoms have raised concern relating to the management of people who are nearing the end of life. In this review, the numbers of participants experiencing these symptoms were low. </p> </section> <section id="CD011460-sec-0053"> <h3 class="title" id="CD011460-sec-0053">Overall completeness and applicability of evidence</h3> <p>Tapentadol was first licensed for use in the UK and USA in 2011. To date, there are just three completed studies published worldwide, with approximately 1000 participants. We anticipate that more trials will be undertaken. The current published trials give some indication of the place of this analgesic in managing cancer pain. </p> </section> <section id="CD011460-sec-0054"> <h3 class="title" id="CD011460-sec-0054">Quality of the evidence</h3> <p>The included studies were generally of good quality, although one study was an open‐label study that could have been blinded (<a href="./references#CD011460-bbs2-0002" title="ImanakaK , TominagaY , EtropolskiM , OhashiH , HiroseK , MatsumuraT . Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clinical Drug Investigation2014;34(7):501-11. [DOI: 10.1007/s40261-014-0204-3] [Clinicaltrials.gove identifier: NCT01309386]Janssen PharmaceuticalKK . A safety and efficacy study of oral tapentadol extended-release in Japanese participants. www.clinicaltrials.gov/ct2/show/NCT01309386 (accessed 14 January 2015)2013. [CTG: NCT01309386]">Imanaka 2014</a>), and all studies had fewer than 200 participants per treatment arm. Clinically useful outcomes were reported for both efficacy and harm in all studies. </p> </section> <section id="CD011460-sec-0055"> <h3 class="title" id="CD011460-sec-0055">Potential biases in the review process</h3> <p>We carried out a thorough search for studies and feel it is unlikely that we have missed any large body of research. The different study designs precluded any pooling of data, so we reported results in a narrative manner. </p> </section> <section id="CD011460-sec-0056"> <h3 class="title" id="CD011460-sec-0056">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of any other up‐to‐date reviews of oral tapentadol for cancer pain.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011460-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/urn:x-wiley:14651858:media:CD011460:CD011460-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011460-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/image_n/nCD011460-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/image_t/tCD011460-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/full#CD011460-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/image_n/nCD011460-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011460-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/urn:x-wiley:14651858:media:CD011460:CD011460-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011460-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/image_n/nCD011460-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/image_t/tCD011460-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/full#CD011460-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/image_n/nCD011460-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011460-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/urn:x-wiley:14651858:media:CD011460:CD011460-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011460-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/image_n/nCD011460-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/image_t/tCD011460-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/full#CD011460-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011460.pub2/media/CDSR/CD011460/image_n/nCD011460-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011460.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011460-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011460-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011460-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD011460-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011460-note-0008">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011460-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD011460-note-0004">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011460-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011460\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011460\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011460\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011460\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011460\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011460.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011460.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011460.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011460.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011460.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727533291"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011460.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727533295"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011460.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eae65db4cf573',t:'MTc0MDcyNzUzMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 